Journal article
Low-dose sirolimus in retroperitoneal lymphangioleiomyomas
Lung India, Vol.36(4), pp.349-352
07/01/2019
DOI: 10.4103/lungindia.lungindia_433_18
PMCID: PMC6625232
PMID: 31290423
Abstract
Lymphangioleiomyomatosis (LAM) is a rare disease associated with cystic lung destruction and abdominal tumors, including lymphangioleiomyomas, which frequently occur in the retroperitoneal region. Sirolimus therapy is currently recommended for LAM patients with abnormal or declining lung function with an adjusted dose to maintain a serum trough level of 5-15 ng/mL. We describe a significant reduction of retroperitoneal lymphangioleiomyomas after treatment with low-dose sirolimus therapy (serum trough level <5 ng/mL) in a patient with sporadic LAM.
Details
- Title: Subtitle
- Low-dose sirolimus in retroperitoneal lymphangioleiomyomas
- Creators
- Kamonpun Ussavarungsi - University of IowaArchana T. Laroia - University of IowaCharles D. Burger - Division of Pulmonary and Critical Care, Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA
- Resource Type
- Journal article
- Publication Details
- Lung India, Vol.36(4), pp.349-352
- DOI
- 10.4103/lungindia.lungindia_433_18
- PMID
- 31290423
- PMCID
- PMC6625232
- NLM abbreviation
- Lung India
- ISSN
- 0970-2113
- eISSN
- 0974-598X
- Publisher
- Wolters Kluwer Medknow Publications
- Number of pages
- 4
- Language
- English
- Date published
- 07/01/2019
- Academic Unit
- Radiology; Pulmonary, Critical Care, and Occupational Medicine; Internal Medicine
- Record Identifier
- 9984318718702771
Metrics
2 Record Views